Zealand Pharma A/S (ZEAL.CO)
DKK 802.5
(0.44%)
DKK 802.5
(0.44%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -425.66 Million | -942.2 Million | -1.21 Billion | -688.71 Million | -409.45 Million | -460.4 Million |
| Net Income | -703.73 Million | -1.2 Billion | -1.01 Billion | -846.72 Million | -571.54 Million | 581.28 Million |
| Depreciation & Amortization | 28.3 Million | 117.96 Million | 40.24 Million | 42.69 Million | 13.68 Million | 4.5 Million |
| Deferred income taxes | -94.46 Million | - | -1.19 Million | 9.86 Million | -5.38 Million | 43.77 Million |
| Stock-based compensation | 61.42 Million | 52.28 Million | 53.5 Million | 30.48 Million | 14.76 Million | 17.46 Million |
| Change in working capital | 52.1 Million | 10.26 Million | -166.32 Million | 97.81 Million | 10.87 Million | 12.78 Million |
| Other non-cash items | 230.7 Million | 79.12 Million | -120.06 Million | -22.84 Million | 128.15 Million | -1.12 Billion |
| Investing Cash Flow | -1.09 Billion | 281.25 Million | -18.12 Million | -196.8 Million | -51.66 Million | 881.9 Million |
| Investments in PPE | -23.74 Million | -11.71 Million | -22.13 Million | -25.04 Million | -23.51 Million | -4.03 Million |
| Acquisitions | 1.08 Billion | 106.38 Million | - | -167.79 Million | 25 Thousand | - |
| Investment purchases | -2.15 Billion | -700.47 Million | - | - | -22.8 Million | -299.84 Million |
| Sales/Maturities of investments | 1.08 Billion | 887.06 Million | - | - | -25 Thousand | 74.23 Million |
| Other Investing Activities | -1.08 Billion | 292.96 Million | 4.01 Million | -3.97 Million | -5.34 Million | 1.11 Billion |
| Financing Cash Flow | 907.01 Million | 587.39 Million | 1.33 Billion | 760.94 Million | 674.48 Million | -155.44 Million |
| Debt repayment | -525.76 Million | -436.08 Million | -14.71 Million | -29.21 Million | -8.68 Million | -158.31 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -41.6 Million | - | -28.59 Million | - | - | - |
| Common Stock Issuance | 1.49 Billion | 1.08 Billion | 775.04 Million | 832.86 Million | 697.61 Million | 2.86 Million |
| Other Financing Activities | -17.66 Million | -61.17 Million | 1.24 Billion | -42.7 Million | -14.44 Million | 2.86 Million |
| Accounts receivables | -18.6 Million | 18.22 Million | -64.49 Million | -7.71 Million | -21.05 Million | -471 Thousand |
| Accounts payables | 32.83 Million | -58.64 Million | -49.05 Million | 119.93 Million | 17.06 Million | 13.25 Million |
| Inventory | 9.33 Million | 50.69 Million | -52.77 Million | -14.4 Million | 3.99 Million | - |
| Other working capital | 28.53 Million | -67.58 Million | -30.18 Million | -42.88 Million | 10.87 Million | - |
| Cash at beginning of period | 1.06 Billion | 1.12 Billion | 960.22 Million | 1.08 Billion | 860.63 Million | 588.71 Million |
| Cash at end of period | 449.31 Million | 1.06 Billion | 1.12 Billion | 960.22 Million | 1.08 Billion | 860.63 Million |
| Capital Expenditure | -23.74 Million | -11.71 Million | -22.13 Million | -25.04 Million | -23.51 Million | -4.03 Million |
| Effect of forex changes on cash | -7.23 Million | 13.68 Million | 66.22 Million | 3.74 Million | 7.06 Million | 5.86 Million |
| Net cash flow / Change in cash | -619.92 Million | -59.86 Million | 168.88 Million | -120.83 Million | 220.42 Million | 271.91 Million |
| Free Cash Flow | -449.41 Million | -953.91 Million | -1.23 Billion | -713.76 Million | -432.97 Million | -464.43 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -292.75 Million | -228.64 Million | -703.73 Million | -264.75 Million | 74.14 Million | -319.5 Million |
| Depreciation & Amortization | 6.76 Million | 6.61 Million | 28.3 Million | 20.12 Million | - | 12.77 Million |
| Deferred income taxes | - | - | -94.46 Million | -81.55 Million | - | - |
| Stock-based compensation | 22.45 Million | 18.16 Million | 61.42 Million | 61.42 Million | - | 16.92 Million |
| Change in working capital | 9.02 Million | -4.56 Million | 52.1 Million | 263.46 Million | -176.31 Million | 4.82 Million |
| Other non-cash items | 49.57 Million | -1.57 Million | 230.7 Million | -20.75 Million | -10.53 Million | 138.87 Million |
| Investing Cash Flow | -30.42 Million | -1.37 Billion | -1.09 Billion | 6.69 Million | 160.16 Million | -1.19 Billion |
| Investments in PPE | -6.08 Million | -3.53 Million | -23.74 Million | -10.38 Million | -9.67 Million | -2.56 Million |
| Acquisitions | - | - | 1.08 Billion | -13.41 Million | 8.84 Million | 1.19 Billion |
| Investment purchases | -535.3 Million | -1.78 Billion | -2.15 Billion | -411.95 Million | -285.92 Million | -1.29 Billion |
| Sales/Maturities of investments | 510.96 Million | 409.82 Million | 1.08 Billion | 429.03 Million | 455.76 Million | 97.22 Million |
| Other Investing Activities | -25.33 Million | -1.37 Billion | -1.08 Billion | 13.41 Million | -8.84 Million | -1.19 Billion |
| Financing Cash Flow | 6.74 Billion | 1.82 Billion | 907.01 Million | 5.59 Million | 4.03 Million | 867.22 Million |
| Debt repayment | -3.82 Million | -369.86 Million | -525.76 Million | -8.62 Million | -2.68 Million | -525.76 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -81.03 Million | - | -41.6 Million | - | - | -41.6 Million |
| Common Stock Issuance | 6.82 Billion | 1.45 Billion | 1.49 Billion | 14.22 Million | 6.71 Million | 1.5 Billion |
| Other Financing Activities | -3.82 Million | 1.45 Billion | -17.66 Million | -8.62 Million | 4.03 Million | 492.69 Million |
| Accounts receivables | -26.48 Million | 9.36 Million | -18.6 Million | -6.75 Million | - | - |
| Accounts payables | 33.95 Million | 3.34 Million | 32.83 Million | 39.83 Million | - | - |
| Inventory | 2.11 Million | 5.01 Million | 9.33 Million | 9.33 Million | - | 721 Thousand |
| Other working capital | -559 Thousand | -22.29 Million | 28.53 Million | 260.88 Million | -176.31 Million | 4.82 Million |
| Cash at beginning of period | 672.39 Million | 449.31 Million | 1.06 Billion | 384.44 Million | 327.68 Million | 831.07 Million |
| Cash at end of period | 7.15 Billion | 672.39 Million | 449.31 Million | 449.31 Million | 384.44 Million | 327.68 Million |
| Capital Expenditure | -6.08 Million | -3.53 Million | -23.74 Million | -10.38 Million | -9.67 Million | -2.56 Million |
| Effect of forex changes on cash | 945 Thousand | 3.62 Million | -7.23 Million | -6.94 Million | 5.26 Million | 1.23 Million |
| Net cash flow / Change in cash | 6.48 Billion | 223.08 Million | -619.92 Million | 64.87 Million | 56.75 Million | -503.39 Million |
| Free Cash Flow | -237.41 Million | -227.2 Million | -449.41 Million | 49.12 Million | -122.37 Million | -178.37 Million |
4366
FSKRS
BERGEPAINT
AARTIDRUGS
IRRA
300214